DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Omaveloxolone is an investigational drug.
There have been 10 clinical trials for Omaveloxolone. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Melanoma, Muscular Diseases, and Mitochondrial Myopathies. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., AbbVie, and Friedreich's Ataxia Research Alliance.
There are three US patents protecting this investigational drug and forty-two international patents.
Recent Clinical Trials for Omaveloxolone
|A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone||Covance||Phase 1|
|A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone||Reata Pharmaceuticals, Inc.||Phase 1|
|A Human AME Study for Omaveloxolone||Reata Pharmaceuticals, Inc.||Phase 1|
Top disease conditions for Omaveloxolone
Top clinical trial sponsors for Omaveloxolone
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Omaveloxolone||Start Trial||2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof||Reata Pharmaceuticals, Inc. (Irving, TX)||Start Trial|
|Omaveloxolone||Start Trial||A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof||REATA PHARMACEUTICALS, INC. (Irving, TX)||Start Trial|
|Omaveloxolone||Start Trial||2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof||REATA PHARMACEUTICALS, INC. (Irving, TX)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|